Namyang Dairy chairman files answer with court just before deadline Answer submitted four months after Hahn & Co filed lawsuit against Hong won-sik
Translated by Ryu Ho-joung 공개 2022-01-05 08:11:28
이 기사는 2022년 01월 05일 08:07 thebell 에 표출된 기사입니다.
Hong Won-sik, owner and chairman of Namyang Dairy Products, submitted a written answer to a court through his representing law firm LKB& Partners just before the deadline set by a judge in the first hearing.The answer was filed with the Seoul Central District Court on December 31, more than four months after private equity firm Hahn & Company filed a lawsuit in August last year against Hong and his family demanding the execution of the share purchase agreement between the two parties.
Hong’s slow response is seen by some legal experts as a tactical move to postpone the trial. During the first hearing, which was held on December 2, an attorney representing Hong and his family said the filing of the answer could be completed by the next hearing date.
But the judge did not accept this and asked the defendants to submit the answer within 30 days after the first hearing date.
According to the information filed with the court by LKB& Partners on December 31, an additional attorney at the law firm joined the case.
Hong has yet to inform the court of whether he has hired an additional law firm, which was cited as one of the reasons for the delay of the defendant answer in the first hearing.
Legal sources said Hong has consulted a law firm that specializes in cases involving mergers and acquisitions and corporate ownership apart from LKB& Partners.
A second hearing is scheduled for January 13. (Reporting by Gyoung-tae Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [ICTK road to IPO]자금사용 계획에 ‘매출 초과달성’ 자신감 표출
- [K-바이오 클러스터 기행|대전]현실에서 쌓은 노하우, 집단지성의 믿음 '대전 CFO모임'
- 핑거랩스, 엑스클루시브 플랫폼 '비긴즈유스' 공개
- 초록뱀미디어, 웹3.0 'BTS화양연화' 기반 창작 드라마 사전판매 호조
- 종근당, 케이캡 공백에도 1분기 매출 '선방'
- 보로노이, 또 '기술반환' 반전 키는 'VRN07'
- '2세 경영' 이디야, '역성장' 위기 고리 끊는다
- 이디야, '2세 문승환' 경영전략본부장으로 '재직'
- [클리니컬 리포트]지아이이노베이션, IL-2 면역항암제 승부수 'SC 추가'
- [VC 투자기업]울트라브이, 교보증권 주관사로…스팩 우회 상장 고려